Lilly rejoins KRAS race with swipe at Amgen and Mirati, plans 2021 clinical trial

Eli Lilly has rejoined the KRAS race months after toxicity forced it to dump its first candidate. The Big Pharma is set to enter phase 1 later this year with a new drug it compared favorably to rival assets developed by Amgen and Mirati Therapeutics.